CoChat

Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial

Cayla, Guillaume, Cuisset, Thomas, Silvain, Johanne, Leclercq, Florence, Manzo-Silberman, Stephane, Saint-Etienne, Christophe, Delarche, Nicolas, Bellemain-Appaix, Anne, Range, Grégoire, El Mahmoud, Rami, Carrié, Didier, Belle, Loic, Souteyrand, Geraud, Aubry, Pierre, Sabouret, Pierre, du Fretay, Xavier Halna, Beygui, Farzin, Bonnet, Jean-Louis, Lattuca, Benoit, Pouillot, Christophe, Varenne, Olivier, Boueri, Ziad, Van Belle, Eric, Henry, Patrick, Motreff, Pascal, Elhadad, Simon, Salem, Joe-Elie, Abtan, Jérémie, Rousseau, Hélène, Collet, Jean-Philippe, Vicaut, Eric, Montalescot, Gilles · 2016 · The Lancet

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

Abstract

Background Elderly patients are at high risk of ischaemic and bleeding events. Platelet function monitoring offers the possibility to individualise antiplatelet therapy to improve the therapeutic risk-benefit ratio. We aimed to assess the effect of platelet function monitoring with treatment adjustment in elderly patients stented for an acute coronary syndrome.Methods We did this multicentre, open-label, blinded-endpoint, randomised controlled superiority study at 35 centres in France. Patients aged 75 years or older who had undergone coronary stenting for acute coronary syndrome were randomly assigned (1:1), via a central interactive voice-response system based on a computer-generated permuted-block randomisation schedule with randomly selected block sizes, to receive oral prasugrel 5 mg daily with dose or drug adjustment in case of inadequate response (monitoring group) or oral prasugrel 5 mg daily with no monitoring or treatment adjustment (conventional group). Randomisation was stratified by centre. Platelet function testing was done 14 days after randomisation and repeated 14 days after treatment adjustment in patients in the monitoring group. Study investigators and patients were not masked to treatment allocation, but allocation was concealed from an independent clinical events committee responsible for endpoint adjudication. The primary endpoint was a composite of cardiovascular death, myocardial infarction, stroke, stent thrombosis, urgent revascularisation, and Bleeding Academic Research Consortium-defined bleeding complications (types 2, 3, or 5) at 12 months' follow-up. We did analysis by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01538446.Findings Between March 27, 2012, and May 19, 2015, we randomly assigned 877 patients to the monitoring group (n=442) or the conventional group (n=435). The primary endpoint occurred in 120 (28%) patients in the monitoring group compared with 123 (28%) patients in the conventional group (hazard ratio [HR], 1·003, 95% CI 0·78-1·29; p=0·98). Rates of bleeding events did not differ significantly between groups.Interpretation Platelet function monitoring with treatment adjustment did not improve the clinical outcome of elderly patients treated with coronary stenting for an acute coronary syndrome. Platelet function testing is still being used in many centres and international guidelines still recommend platelet function testing in high-risk situations. Our study does not support this practice or these recommendations.Funding Eli Lilly and Company, Daiichi Sankyo, Stentys, Accriva Diagnostics, Medtronic, and Fondation Coeur et Recherche.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(16)31323-x

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Research works printed but not linked: 1

  1. Kolh, 2014, ESC/EACTS myocardial revascularization guidelines 2014, Eur Heart J, 35, 3235

Cited by

See all 387

Metadata

Authors
Cayla, G., Cuisset, T., Silvain, J., Leclercq, F., Manzo-Silberman, S., Saint-Etienne, C., Delarche, N., Bellemain-Appaix, A., Range, G., El Mahmoud, R., Carrié, D., Belle, L., Souteyrand, G., Aubry, P., Sabouret, P., du Fretay, X. H., Beygui, F., Bonnet, J.-L., Lattuca, B., Pouillot, C., Varenne, O., Boueri, Z., Van Belle, E., Henry, P., Motreff, P., Elhadad, S., Salem, J.-E., Abtan, J., Rousseau, H., Collet, J.-P., Vicaut, E., & Montalescot, G.
Affiliations
  • Université de Montpellier (FR)
  • Inserm (FR)
  • Centre Hospitalier Universitaire de Montpellier (FR)
  • Centre Hospitalier De Pau (FR)
  • Centre Hospitalier Universitaire de Toulouse (FR)
  • Hôpital Bichat-Claude-Bernard (FR)
  • Centre Hospitalier Universitaire de Caen Normandie (FR)
  • Hôpital Cochin (FR)
  • Hôpital Lariboisière (FR)
  • Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
Corresponding author
Montalescot, Gilles
Venue
The Lancet
Publisher
Elsevier BV
Published
2016-10
Volume
388
Issue
10055
Pages
2015-2022
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2509918966
Cited by
380
References
39
Citations by year
2026: 17 · 2025: 27 · 2024: 25 · 2023: 38 · 2022: 42 · 2021: 43 · 2020: 35 · 2019: 40 · 2018: 61 · 2017: 43 · 2016: 8
FWCI
41.85
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Keywords
monitoring, antiplatelet therapy, prasugrel, elderly patients, acute coronary syndrome, coronary stenting, bleeding complications, stent thrombosis, major adverse cardiovascular events, individualised medicine, dual antiplatelet therapy, clopidogrel, ticagrelor, glycoprotein IIb/IIIa inhibitors, bleeding risk stratification, benefits and risks
MeSH terms
Prasugrel Hydrochloride, Aged, Aged, 80 and over, Drug Administration Schedule, Female, Humans, Male, Monitoring, Physiologic, Platelet Aggregation Inhibitors, Platelet Function Tests, Stents, Risk Assessment, Acute Coronary Syndrome, Percutaneous Coronary Intervention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. https://app.cochat.ai/papers/10.1016/s0140-6736(16)31323-x
The paper
Cayla, G., Cuisset, T., Silvain, J., Leclercq, F., Manzo-Silberman, S., Saint-Etienne, C., Delarche, N., Bellemain-Appaix, A., Range, G., El Mahmoud, R., Carrié, D., Belle, L., Souteyrand, G., Aubry, P., Sabouret, P., du Fretay, X. H., Beygui, F., Bonnet, J.-L., Lattuca, B., . . . Montalescot, G. (2016). Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. The Lancet. https://doi.org/10.1016/s0140-6736(16)31323-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.